Results 31 to 40 of about 51,582 (258)

Diagnostic and Therapeutic Challenges in Statin-Induced Necrotizing Autoimmune Myopathy in an Elderly Patient: A Rare Case Report. [PDF]

Clin Case Rep
ABSTRACT We present the case of a 78‐year‐old woman with metabolic syndrome and a history of multiple ischemic strokes who developed progressive symmetrical proximal muscle weakness, predominantly affecting the lower extremities, while on atorvastatin.
Shrestha N, Hassan A, Evans JA.
europepmc   +2 more sources

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Switching Therapy to the Second Brand of Generic Atorvastatin: A 6-Month Retrospective Cohort, Real-World Study

Drugs - Real World Outcomes
Introduction High levels of low-density lipoprotein-cholesterol (LDL) is a major risk factor for cardiovascular diseases. While treatment with atorvastatin is beneficial, the original atorvastatin may be cost prohibitive to some patients.
Panisa Manasirisuk, Somsak Tiamkao, Chaiyasith Wongvipaporn, Nanthaphan Chainirun, Kittisak Sawanyawisuth   +4 more
doaj   +1 more source

Absence of a significant pharmacokinetic interaction between atorvastatin and fenofibrate: A randomized, crossover, study of a fixed-dose formulation in healthy Mexican subjects

Frontiers in Pharmacology, 2015
Several clinical trials have substantiated the efficacy of the co-administration of statins like atorvastatin and fibrates. Without information currently available about the interaction between the two drugs, a pharmacokinetic study was conducted to ...
Omar ePatiño-Rodríguez, Rosa María eMartínez-Medina, Irma eTorres-Roque, Maricela eMartínez-Delgado, America Susana Mares-Garcia, Abraham eEscobedo-Moratilla, Amador eCovarrubias-Pinedo, Angélica eArzola-Paniagua, José Luis eHerrera-Torres, José ePérez-Urizar   +9 more
doaj   +1 more source

Atorvastatin-induced CD59 and decay-accelerating factor in hypoxia enhance endothelial cell cytoprotection

, 2011
Copyright information:Taken from "Statin-induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis"Arthritis Research & Therapy 2006;8(4):R130-R130.Published ...
Sarah K Harten (23391), Patrick H Maxwell (23394), Anne R Kinderlerer (23388), Michael Johns (23390), Rivka Steinberg (23389), Elaine A Lidington (23392), Justin C Mason (23395), Dorian O Haskard (23393)   +7 more
core   +1 more source

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The quantitative effect of several inhibitory drugs on the development of adverse drug reactions (ADRs) is currently difficult to estimate. Our aim was to identify metabolic pathways, which, when inhibited, increase the risk for certain ADRs, and to use this system to consider comedication at individual level. Methods Data of a prospective
Judith Berres, Justyna Wozniak, Hannah Fölsch, Anja Knueppel‐Ruppert, Verena Graeff, Andrea Kriegisch‐Stumpf, Harald Dormann, Julia C. Stingl, Katja S. Just   +8 more
wiley   +1 more source

Effect of polymorphisms in drug metabolism and transportation on plasma concentration of atorvastatin and its metabolites in patients with chronic kidney disease

Frontiers in Pharmacology, 2023
Dyslipidemia due to renal insufficiency is a common complication in patients with chronic kidney diseases (CKD), and a major risk factor for the development of cardiovascular events.
Zebin Jiang, Zemin Wu, Ruixue Liu, Qin Du, Xian Fu, Min Li, Yongjun Kuang, Shen Lin, Jiaxuan Wu, Weiji Xie, Ganggang Shi, Yanqiang Peng, Fuchun Zheng, Fuchun Zheng   +13 more
doaj   +1 more source

Patients on statins with elevated transaminases: Frequency of follow‐up creatine kinase testing and gastroenterology referral

British Journal of Clinical Pharmacology, EarlyView.
Abstract Purpose To quantify how often creatine kinase (CK) is measured after newly elevated aminotransferases in statin users, and whether absent CK data are associated with gastroenterology (GI) referrals. Methods Retrospective chart review of adult outpatients on statins with a first alanine/aspartate aminotransferase (ALT/AST) elevation during a 5 ...
Faris Shweikeh, Anas Kartoumah, Rajshri Joshi, Anjali Nadihaan, Mohammed Mouchli, Inderprit Singh   +5 more
wiley   +1 more source

A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD

, 2002
A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.BackgroundIndividuals with chronic renal disease are at high risk of cardiovascular morbidity and mortality, and therefore the management of dyslipidemia is ...
Harris, Kevin P.G., the Atorvastatin in CAPD Study Investigators,, Chong, Camilla C., Wheeler, David C.   +3 more
core   +1 more source

A prospective series of acute rivaroxaban overdose, coagulopathy and bleeding complications (ATOM 11)

British Journal of Clinical Pharmacology, EarlyView.
Aim There is limited research describing rivaroxaban overdose. We aim to describe rivaroxaban overdose, coagulopathy and bleeding complications. Methods This is a prospective series of acute adult (>14 years) rivaroxaban overdose presentations >40 mg enrolled in the Australian Toxicology Monitoring study and presenting to three Australian clinical ...
Katherine Z. Isoardi, Angela L. Chiew, Keith Harris, Geoffrey K. Isbister   +3 more
wiley   +1 more source